Literature DB >> 8857931

Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.

B J Bain1.   

Abstract

Hypereosinophilic syndromes may result either from eosinophilic differentiation of a clone of neoplastic cells or from reactive eosinophilia. In other patients HES is idiopathic. It appears likely that in many patients the "idiopathic' hypereosinophilic syndrome is actually a chronic myeloproliferative disorder. Those cases showing an increase of blast cells or a demonstrable clonal cytogenetic abnormality should be classified as eosinophilic leukaemia. In other cases the neoplastic nature of the disease can be recognized only in retrospect when a granulocytic sarcoma or AMI, develops. A few cases of idiopathic HES are consequent on cytokine secretion whereas others remain idiopathic at the time of death. When eosinophilia occurs as a feature of an acute or chronic myeloid leukaemia or a chronic myeloproliferative disorder the eosinophils are usually part of the leukaemic clone. However, eosinophilia in association with acute lymphoblastic leukaemia is usually reactive. Rare cases have a biphenotypic leukaemia/lymphoma with both eosinophils and lymphoid cells arising from a mutant pluripotent stem cell.

Entities:  

Mesh:

Year:  1996        PMID: 8857931

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Cardiac disease in a case of precursor B acute lymphoblastic leukaemia with eosinophilia(ALL/Eo).

Authors:  Mehrnaz Asadi Gharabaghi; Pegah Aghajanzadeh; Ghazal Zahedi; Roghayyeh Borji; Leila Derakhskan; Roya Sattarzadeh; Ramezanali Sharaifian
Journal:  BMJ Case Rep       Date:  2012-01-20

2.  New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.

Authors:  T Berki; M Dávid; B Bóné; H Losonczy; J Vass; P Németh
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Hypereosinophilia and metastatic anaplastic carcinoma of unknown primary.

Authors:  H Abali; M K Altundag; H Engin; O O Altundag; A Türker; A Uner; S Ruacan
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

4.  Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.

Authors:  Yasuhiro Tanaka; Masayuki Kurata; Katsuhiro Togami; Haruyuki Fujita; Naoko Watanabe; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Akiko Sada; Toshimitsu Matsui; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 5.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 6.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Thomas B Nutman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

7.  Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.

Authors:  D Tan; W Hwang; H J Ng; Y T Goh; P Tan
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

8.  Hypereosinophilic syndrome.

Authors:  C Venkatesh; E Mahender; S Janani; S Malathi; M Vijayakumar; B R Nammalwar
Journal:  Indian J Pediatr       Date:  2006-03       Impact factor: 5.319

9.  Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13, +15 double trisomy resulting in an adverse outcome.

Authors:  Peter McGrattan; Mervyn Humphreys; Donald Hull; Mary F McMullin
Journal:  Ulster Med J       Date:  2007-09

10.  Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

Authors:  Sa A Wang; Robert P Hasserjian; Wayne Tam; Albert G Tsai; Julia T Geyer; Tracy I George; Kathryn Foucar; Heesun J Rogers; Eric D Hsi; Bryan A Rea; Adam Bagg; Carlos E Bueso-Ramos; Daniel A Arber; Srdan Verstovsek; Attilio Orazi
Journal:  Haematologica       Date:  2017-05-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.